SFZN.SW Siegfried (SIX) pre-market 20 Feb 2026 earnings: EPS and guidance eyed

We open pre-market on 20 Feb 2026 with SFZN.SW stock at CHF 90.00, ahead of Siegfried Holding AG’s earnings due later today. Investors will watch EPS CHF 3.51 and management guidance for margin recovery. The company reports after regional markets open, and trading volume of 85,355 shares suggests moderate attention.

Earnings preview: SFZN.SW stock expectations

Siegfried (SFZN.SW) reports on 20 Feb 2026. Analysts will focus on reported EPS CHF 3.51 and any update to full-year guidance. The 50-day average price is CHF 83.07 and the 200-day average is CHF 85.23, both below today’s price of CHF 90.00, signaling recent strength ahead of results.

We expect commentary on contract-manufacturing volumes and pricing. Recent three-month gains of 30.43% increase scrutiny on sustainable margin drivers and order backlog conversion.

What to watch in the SFZN.SW earnings report

Key items: revenue growth, sterile-fill utilisation, and free cash flow. Siegfried’s trailing free cash flow per share is -0.55, so investors will judge whether operating cash flow recovers versus capex.

Also monitor working capital changes: days sales outstanding 89.42 and days inventory on hand 178.97 are long. Any reduction would materially improve cash conversion.

Valuation and financial metrics for SFZN.SW stock

Siegfried trades at PE 25.64 on EPS 3.51 with market cap CHF 3,939,144,300.00. Price-to-sales is 3.05 and price-to-book is 3.86, below some healthcare peers on growth-adjusted metrics. The healthcare sector average PE is 35.01, so SFZN.SW looks cheaper on PE terms.

Margins look healthy: operating margin 15.21% and net margin 11.91%. Debt to equity is moderate at 0.45, and interest coverage is strong at 26.50, limiting near-term financial risk.

Meyka Grade and technicals for SFZN.SW stock

Meyka AI rates SFZN.SW with a score of 75.14 out of 100 — Grade B+ — BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are informational and not financial advice.

On technicals RSI is 50.63, ADX 39.67 signals a strong trend, and Bollinger upper/lower bands are CHF 101.53 / CHF 85.44. Short-term momentum indicators are mixed, so price reaction to results may drive intraday direction.

Analyst view and price targets for SFZN.SW stock

Consensus price-target data is limited. For scenario planning we set a conservative base case target CHF 80.00, a central case CHF 95.00, and a bull case CHF 105.00. These reflect earnings mix, margin recovery, and sector multiples.

Market-implied expectations appear moderate. Average daily volume 122,772 suggests liquidity is adequate for institutional flows that could re-rate shares after a clear guidance update.

Risks and catalysts in the SFZN.SW outlook

Risks: slower conversion of contract wins, continued negative free cash flow per share -0.55, and inventory cycles. Regulatory or product-quality issues would also weigh on shares.

Catalysts: stronger-than-expected EBITDA, improvement in operating cash flow, and clearer medium-term guidance on sterile-fill capacity could push the stock above recent highs (Year High CHF 101.60).

Final Thoughts

Key takeaways for SFZN.SW stock: Siegfried enters the 20 Feb 2026 report with CHF 90.00 per share, a trailing PE of 25.64, and a solid operating margin of 15.21%. Meyka AI’s forecast model projects a three-year price of CHF 92.07, implying an upside of 2.30% versus today’s price. Our scenario targets range from CHF 80.00 (bear) to CHF 105.00 (bull), with a central case near CHF 95.00. Watch EPS, guidance, and cash-flow commentary; any meaningful pickup in free cash flow would be the clearest near-term rerating catalyst. Forecasts are model-based projections and not guarantees. Meyka AI provides this as an AI-powered market analysis platform to inform your research.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.